Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction

BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there are limited efficacy data related to dose modifications. Given the prevalence of HCC in South Texas, we assessed the e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Al-Rajabi, Raed, Patel, Sukeshi, Ketchum, Norma S., Jaime, Nicole A., Lu, Ting-Wei, Pollock, Brad H., Mahalingam, Devalingam
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4397242/
https://ncbi.nlm.nih.gov/pubmed/26029452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados